STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
146
13F, latest reported quarter
Conversions, 180 days
7
Codes C/M, not in net · $624.1K priced
What the filings say about PRLB
Insiders, 180 days
-$2.7M net sold
3 sellers · 27% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$2.1M
6 notices
Proto Labs insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Proto Labs Inc insiders sold a net $2.7M of stock across 19 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Sep 17, 2026.
The trade is 14.3% of the 35,019 shares held after it.
No other insider sold within 30 days.
146 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Schumacher Daniel sold about $476.6K of PRLB under a 10b5-1 plan on Sep 24, 2026; 146 funds added in the latest 13F quarter.
1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Sep 16, 2026.
The trade is 12.2% of the 40,019 shares held after it.
No other insider sold within 30 days.
146 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Schumacher Daniel sold about $417.5K of PRLB under a 10b5-1 plan on Sep 17, 2026; 146 funds added in the latest 13F quarter.
First Form 4 purchase or sale (code P or S) here by this insider on our record.
The trade is 0.2% of the 44,919 shares held after it.
No other insider sold within 30 days.
146 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Schumacher Daniel sold about $8.5K of PRLB under a 10b5-1 plan on Sep 16, 2026; 146 funds added in the latest 13F quarter.
First Form 4 purchase or sale (code P or S) here by this insider on our record.
The trade is 4.5% of the 33,005 shares held after it.
1 other insider sold within 30 days.
146 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director WEHRWEIN SVEN sold about $115.4K of PRLB on Jun 2, 2026; 1 other insider sold within 30 days and 146 funds added in the latest 13F quarter.
First Form 4 purchase or sale (code P or S) here by this insider on our record.
The trade is 1.5% of the 32,505 shares held after it.
1 other insider sold within 30 days.
146 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director WEHRWEIN SVEN sold about $39.2K of PRLB on Jun 2, 2026; 1 other insider sold within 30 days and 146 funds added in the latest 13F quarter.
19 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Nobody has filed for crossing 5%. That is a fact, not missing data.
PRLB planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
MICHAEL R KENISON
Filed 2026-09-25
$109.5K
MICHAEL R KENISON
Filed 2026-09-24
$172.5K
DANIEL SCHUMACHER
Filed 2026-09-24
$445.6K
DANIEL SCHUMACHER
Filed 2026-09-17
$407.9K
DANIEL SCHUMACHER
Filed 2026-09-16
$7.9K
PRLB mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Pacer BlueStar Engineering the Future ETF
$1.2M position · as of 2026-07-31
8.3%
The 3D Printing ETF
$2.2M position · as of 2026-07-31
3.7%
The Disciplined Growth Investors Equity Fund
$4.6M position · as of 2026-07-31
2.7%
The Disciplined Growth Investors Fund
$14.5M position · as of 2026-07-31
2.3%
Zacks Small-Cap Core Fund
$484.9K position · as of 2026-05-31
1.4%
ALPS Disruptive Technologies ETF
$1.0M position · as of 2026-05-31
1.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Robert Bodor
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$4.3M
$4.5M
$1.2M
-74%
+8%
2023
$5.1M
$6.7M
$1.2M
-75%
-15%
2022
$4.6M
$2.0M
$1.0M
-83%
-20%
2020
$3.4M
$6.7M
$1.0M
+51%
+16%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $2.7M sold by insiders over 180 days, 146 funds added last quarter, $2.1M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$560.5M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM PRLB
FY Dec 2025
$533.1M
FY Dec 2024
$500.9M
FY Dec 2023
$503.9M
FY Dec 2022
$488.4M
FY Dec 2021
$488.1M
Jun 2026
$149.3M
Mar 2026
$139.3M
Dec 2025
$136.5M
Sep 2025
$135.4M
Jun 2025
$135.1M
Mar 2025
$126.2M
Dec 2024
$121.8M
Sep 2024
$125.6M
At each fiscal year end
Single quarter
Net margin, TTM
+5.4%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM PRLB
FY Dec 2025
+4.0%
FY Dec 2024
+3.3%
FY Dec 2023
+3.4%
FY Dec 2022
-21.2%
FY Dec 2021
+6.8%
Jun 2026
+6.1%
Mar 2026
+5.8%
Dec 2025
+4.4%
Sep 2025
+5.3%
Jun 2025
+3.3%
Mar 2025
+2.9%
Dec 2024
-0.3%
Sep 2024
+5.7%
At each fiscal year end
Single quarter
Free cash flow, TTM
$56.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM PRLB
FY Dec 2025
$59.7M
FY Dec 2024
$68.7M
FY Dec 2023
$45.2M
FY Dec 2022
$40.4M
FY Dec 2021
$21.0M
Jun 2026
$9.2M
Mar 2026
$14.0M
Dec 2025
$8.4M
Sep 2025
$25.0M
Jun 2025
$9.1M
Mar 2025
$17.1M
Dec 2024
$16.5M
Sep 2024
$23.2M
At each fiscal year end
Single quarter
Debt to equity
0.01x
current debt only, 2017-12-31 (103 months older than the period end); equity 2026-06-30
Debt to equity PRLB
FY Dec 2025
0.01x
FY Dec 2024
0.01x
FY Dec 2023
0.01x
FY Dec 2022
0.01x
FY Dec 2021
0.01x
Jun 2026
0.01x
Mar 2026
0.01x
Dec 2025
0.01x
Sep 2025
0.01x
Jun 2025
0.01x
Mar 2025
0.01x
Dec 2024
0.01x
Sep 2024
0.01x
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
15.70x
TTM operating cash flow over current debt only, 2017-12-31 (103 months older than the period end)
Cash flow to debt PRLB
FY Dec 2025
14.90x
FY Dec 2024
15.57x
FY Dec 2023
14.65x
FY Dec 2022
12.42x
FY Dec 2021
11.05x
Jun 2026
15.70x
Mar 2026
14.73x
Dec 2025
14.90x
Sep 2025
15.07x
Jun 2025
14.20x
Mar 2025
14.97x
Dec 2024
15.57x
Sep 2024
15.55x
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+4.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity PRLB
FY Dec 2025
+3.2%
FY Dec 2024
+2.4%
FY Dec 2023
+2.5%
FY Dec 2022
-13.6%
FY Dec 2021
+4.5%
Jun 2026
+4.5%
Mar 2026
+3.8%
Dec 2025
+3.2%
Sep 2025
+2.2%
Jun 2025
+2.2%
Mar 2025
+2.2%
Dec 2024
+2.4%
Sep 2024
+3.5%
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+4.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets PRLB
FY Dec 2025
+2.8%
FY Dec 2024
+2.2%
FY Dec 2023
+2.2%
FY Dec 2022
-12.0%
FY Dec 2021
+4.0%
Jun 2026
+4.0%
Mar 2026
+3.4%
Dec 2025
+2.8%
Sep 2025
+2.0%
Jun 2025
+2.0%
Mar 2025
+2.0%
Dec 2024
+2.2%
Sep 2024
+3.1%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+4.6%
operating income after a 28.0% effective tax rate, over current debt only, 2017-12-31 (103 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital PRLB
FY Dec 2025
+3.0%
FY Dec 2024
+2.2%
FY Dec 2023
+2.7%
FY Dec 2022
n/a
FY Dec 2021
+5.2%
Jun 2026
+4.6%
Mar 2026
+3.8%
Dec 2025
+3.0%
Sep 2025
+1.9%
Jun 2025
+1.9%
Mar 2025
+1.9%
Dec 2024
+2.2%
Sep 2024
+3.4%
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+5.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed PRLB
FY Dec 2025
+3.6%
FY Dec 2024
+2.8%
FY Dec 2023
+3.9%
FY Dec 2022
-12.2%
FY Dec 2021
+5.1%
Jun 2026
+5.3%
Mar 2026
+4.4%
Dec 2025
+3.6%
Sep 2025
+2.4%
Jun 2025
+2.4%
Mar 2025
+2.5%
Dec 2024
+2.8%
Sep 2024
+4.2%
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
68.49x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing PRLB
FY Dec 2025
57.49x
FY Dec 2024
59.23x
FY Dec 2023
58.15x
FY Dec 2022
n/a
FY Dec 2021
42.44x
Jun 2026
65.21x
Mar 2026
53.79x
Dec 2025
57.49x
Sep 2025
80.69x
Jun 2025
65.64x
Mar 2025
57.44x
Dec 2024
59.23x
Sep 2024
31.24x
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.9B
market value at close 2026-10-23 on 2026-07-28 shares, plus current debt only, 2017-12-31 (103 months older than the period end), minus cash 2026-06-30
Enterprise value PRLB
FY Dec 2025
$1.1B
FY Dec 2024
$874.0M
FY Dec 2023
$925.8M
FY Dec 2022
$640.7M
FY Dec 2021
$1.4B
Jun 2026
$1.8B
Mar 2026
$1.2B
Dec 2025
$1.1B
Sep 2025
$1.1B
Jun 2025
$866.4M
Mar 2025
$771.4M
Dec 2024
$874.0M
Sep 2024
$655.7M
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+2.8%
TTM free cash flow over market value at close 2026-10-23
FCF yield PRLB
FY Dec 2025
+5.0%
FY Dec 2024
+7.2%
FY Dec 2023
+4.5%
FY Dec 2022
+5.8%
FY Dec 2021
+1.5%
Jun 2026
+2.9%
Mar 2026
+4.2%
Dec 2025
+5.0%
Sep 2025
+5.7%
Jun 2025
+6.9%
Mar 2025
+7.9%
Dec 2024
+7.2%
Sep 2024
+6.9%
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.65x
P/E over trailing EPS growth of 105%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing PRLB
FY Dec 2025
1.72x
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
0.62x
Mar 2026
0.73x
Dec 2025
1.72x
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
PRLB ranks highest on financial health (94th percentile) and risk and compliance (86th), and lowest on insider conviction (22nd), among Industrials peers.
Profitability
35
Inputs
Return on equity+4.5% · 39 pct, sector of 198
Return on assets+4.0% · 52 pct, sector of 224
Return on invested capital+4.6% · 11 pct, sector of 107
Return on capital employed+5.3% · 39 pct, sector of 195
Financial health
94
Inputs
Debt to equity0.01x · 89 pct, sector of 214
Cash flow to debt15.70x · 99 pct, sector of 173
Growth
53
Inputs
Revenue growth, YoY+6.4% · 55 pct, sector of 254
Backlog growth, YoY+10.3% · 51 pct, sector of 89
Insider conviction
22
Inputs
Net Form 4 buying (codes P and S), 180d-$1.8M · 44 pct, sector of 170
Insider buyers, 180d0 · 0 pct, sector of 172
Institutional and government
48
Inputs
Funds adding, latest quarter146 · 48 pct, sector of 201
Congress net buyers, 365dno Congress trades in 365 days
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
86
Inputs
Short interest, % of float+3.1% · 62 pct, sector of 269
Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
EPA cases per $1B revenue, 5y0.00 per $1B · 100 pct, sector of 191
New text in Risk Factors, latest 10-K+2.0% · 96 pct, sector of 197
1 not measured: US patents
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
PRLB filings, in plain words
Are Proto Labs insiders buying or selling PRLB?
In the 180 days to 2026-10-27, Proto Labs insiders were net sellers, a net $2.7M across purchases and sales reported on Form 4, by 3 sellers.
Are there planned insider sales of PRLB?
Yes. 6 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $2.1M of stock; the latest, by MICHAEL R KENISON, was filed 2026-09-25.
Read the full summary
In the 180 days to 2026-10-27, Proto Labs insiders were net sellers of PRLB, a net $2.7M across purchases and sales reported on Form 4 by 3 sellers. 27% of the 11 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 6 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $2.1M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.